Adicet Bio Future Growth

Future criteria checks 2/6

Adicet Bio is forecast to grow earnings and revenue by 10.4% and 64.4% per annum respectively while EPS is expected to grow by 12.5% per annum.

Key information

10.4%

Earnings growth rate

12.5%

EPS growth rate

Biotechs earnings growth29.9%
Revenue growth rate64.4%
Future return on equityn/a
Analyst coverage

Good

Last updated15 Aug 2024

Recent future growth updates

Recent updates

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Jul 12
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Adicet Bio: Microcap With A High Risk To Reward Ratio

May 23

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 01
Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Dec 07
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Aug 07
Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Apr 20
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Dec 20
Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Oct 17

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Oct 04
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Aug 16
Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Adicet Bio: A First Take

Jul 22

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Jul 07
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

May 15
Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Mar 18
We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Feb 09

Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management

Dec 28

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Dec 16
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Earnings and Revenue Growth Forecasts

NasdaqGM:ACET - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202629-116-97-1268
12/31/20252-134-92-1109
12/31/2024N/A-123-75-919
6/30/2024N/A-137-93-91N/A
3/31/2024N/A-140-95-92N/A
12/31/2023N/A-143-98-94N/A
9/30/2023N/A-143-100-89N/A
6/30/2023N/A-115-98-83N/A
3/31/2023N/A-105-89-73N/A
12/31/202225-70-62-45N/A
9/30/202230-56-53-39N/A
6/30/202234-48-49-34N/A
3/31/202239-36-47-32N/A
12/31/202110-62-64-51N/A
9/30/202110-55-61-51N/A
6/30/20219-56-52-49N/A
3/31/202112-54-50-48N/A
12/31/202018-37-43-42N/A
9/30/202014-34-37-35N/A
6/30/20204-34-36-35N/A
3/31/20200-28-30-29N/A
12/31/20191-28-29-28N/A
12/31/20188-9-19-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACET is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACET is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACET is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACET's revenue (64.4% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: ACET's revenue (64.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACET's Return on Equity is forecast to be high in 3 years time


Discover growth companies